Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01688791
Other study ID # 8109-001
Secondary ID 2012-002799-14
Status Terminated
Phase Phase 1
First received September 17, 2012
Last updated February 9, 2015
Start date December 2012
Est. completion date September 2014

Study information

Verified date February 2015
Source Endocyte
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial will be conducted in three parts. Part A is a dose escalation trial followed by a dose confirmation trial in folate receptor (FR) 100% endometrial cancer participants. The primary hypothesis of this trial is that administration of vintafolide in combination with carboplatin and paclitaxel is safe and tolerable. Part B is a single dose, dose escalation, pharmacokinetic (PK), and QTc interval trial. The primary objectives include determination of the maximum single tolerated dose of vintafolide and to evaluate the effect of this single maximum dose on the QTc interval. Part C is a weekly dose escalation trial of vintafolide followed by a dose confirmation. The primary hypothesis of this part is that weekly vintafolide has acceptable safety and tolerability in participants with advanced cancers.


Recruitment information / eligibility

Status Terminated
Enrollment 37
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria for all participants:

- Histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist or is unacceptable to the participant

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- At least one measurable metastatic or recurrent lesion

- No history of a previous malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or adequately treated localized prostate carcinoma; or has undergone potentially curative therapy with no evidence of disease for five years

- Adequate organ function

- Female participants of childbearing potential must be willing to use acceptable methods of birth control or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study therapy

- Male participants must agree to use an adequate method of contraception for heterosexual activity starting with the first dose of study therapy through 90 days after the last dose of study therapy

Inclusion criteria for Part A:

- Tumor lesions characterized as folate receptor (FR) 100% as determined by an etarfolide Sequential Single Photon Emission Computed Tomography (SPECT) and CT scan

- Histologically-confirmed diagnosis of locally advanced or metastatic or recurrent endometrial cancer

Inclusion criteria for Parts B & C:

- Must have an etarfolatide SPECT/CT scan to determine FR status

Exclusion criteria for all participants:

- Part A & Part C if enrolled after completion of Part B: Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 4 weeks prior to drug administration, or not recovered from adverse events due to agents administered more than 4 weeks earlier

- Part B: Chemotherapy, radiotherapy, or biological therapy (including monoclonal antibodies) within 3 weeks prior to drug administration, or not recovered from adverse events due to agents administered more than 4 weeks earlier

- Currently participating or has participated in a study with an investigational compound or device within 28 days of initial dosing on this study

- Part A, dose escalation, Parts B and C: More than 3 prior cytotoxic regimens for metastatic disease.

- Part A, dose confirmation: Has received more than 2 prior cytotoxic regimens for metastatic disease.

- Primary central nervous system (CNS) tumor

- Active CNS metastases and/or carcinomatous meningitis.

- Known hypersensitivity to the components of the study therapy or its analogs

- Recent (i.e., = 6 weeks) history of abdominal surgery or peritonitis

- Bowel occlusion or sub-occlusion

- Prior whole abdominal or whole pelvis radiation therapy or radiation therapy to >10% of the bone marrow at any time in the past or prior radiation therapy within the last 3 years to the breast / sternum, head, or neck

- Requires anti-folate therapy for the management of co-morbid conditions

- Known regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse

- Pregnant or breastfeeding or expecting to conceive, or donate sperm within the span of the study

- Human Immunodeficiency Virus (HIV)-positive

- Active Hepatitis B or C

- Symptomatic ascites or pleural effusion.

- History of stem cell or bone marrow transplant

Exclusion Criteria for Part B:

- Permanent pacemaker

- Unable to refrain from use of all concomitant medications on Day 1

- Structural heart disease, history of myocardial infarction (MI), or unstable angina

- History of cardiac arrhythmia, congestive heart failure (CHF), sick sinus syndrome, second or third degree atrioventricular (AV) block

- History of risk factors for Torsades de Pointes such as CHF, uncorrected hypokalemia, family history of long QT syndrome

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vintafolide

Carboplatin

Paclitaxel


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Endocyte

Outcome

Type Measure Description Time frame Safety issue
Primary Parts A and C: Number of participants with dose-limiting toxicities (DLTs) Cycle 1 (21 days) Yes
Primary Part B: Change from Baseline in QTc interval 30 minutes pre-dose and up to 2 hours post-dose Yes
Primary Part C: Number of Participants Experiencing an Adverse Event (AE) Up to 18 weeks (six 3-week cycles) Yes
Secondary Number of participants whose best response is partial response (PR) or complete response (CR) Week 6 No
Secondary Progression free survival Week 6 No
Secondary Disease control rate Week 6 No
Secondary Part B: Pharmacokinetics (PK) of vintafolide, including Area Under the Curve (AUC) and Maximum Concentration (Cmax) Day 1 No
Secondary Part B: PK of Vintafolide Metabolites, including AUC and Cmax Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1